Borkowski, Kamil
Seyfried, Nicholas T.
Arnold, Matthias
Lah, James J.
Levey, Allan I.
Hales, Chadwick M.
Dammer, Eric B.
Blach, Colette
Louie, Gregory
Kaddurah-Daouk, Rima
Newman, John W.
Funding for this research was provided by:
NIA (R01AG069901, R01AG046171)
Emory EHBS (R01 AG070937)
Emory ADRC (P30 AG066511)
FNIH (DAOU16AMPA)
USDA (2032-51530-022-00D)
Article History
Received: 3 March 2023
Accepted: 30 July 2023
First Online: 23 August 2023
Competing interests
: Dr. Kaddurah-Daouk in an inventor on a series of patents on use of metabolomics for the diagnosis and treatment of CNS diseases and holds equity in Metabolon Inc., Chymia LLC and PsyProtix, which were not involved in this study. Matthias Arnold is co-inventor (through Duke University/Helmholtz Zentrum München) on patents on applications of metabolomics in diseases of the central nervous system. Matthias Arnold also holds equity in Chymia LLC and IP in PsyProtix and Atai that is unrelated to this work. Kamil Borkowski (through Duke University/UC Davis) is a coinventor on a patent of targeting lipid mediators in Alzheimer’s disease. All other authors declare that they have no competing interests.